case_images: PMC10896602_01
case_images: Left image showing cross sectional CT imaging of the head, chest, abdomen and pelvis in November 2022, identifying a 24mm left supra-CLAVICULAR soft tissue lesion compatible with a melanoma metastasis. Right image showing cross sectional CT imaging of the head, chest, abdomen and pelvis in October 2023, noting a tiny left supra-clavicular lymph node measuring 6 mm in short axis. This is in keeping with a marked response to ipilimumab and nivolumab combination immunotherapy.
case_images: fonc-14-1330271-g001.jpg
case_images: PMC10896602_01_fonc-14-1330271-g001.jpg
case_images: f1
case_images: CT scan showing good partial response in the axillary and supraclavicular disease ( Figures 1 ,  2 ) and no new sites of disease identified. Considering the marked toxicities experienced, further immunotherapy was suspended.
case_images: Left image showing cross sectional CT imaging of the head, chest, abdomen and pelvis in November 2022, identifying a 40mm left axillary lesion compatible with a melanoma metastasis. Right image showing cross sectional CT imaging of the head, chest, abdomen and pelvis from October 2023, noting the same left axillary lesion measuring 28 mm in short axis. This is consistent with a marked response to ipilimumab and nivolumab combination immunotherapy.
case_images: fonc-14-1330271-g002.jpg
case_images: PMC10896602_01_fonc-14-1330271-g002.jpg
case_images: f2
case_images: CT scan showing good partial response in the axillary and supraclavicular disease ( Figures 1 ,  2 ) and no new sites of disease identified. Considering the marked toxicities experienced, further immunotherapy was suspended.
case_images: Timeline of events relating to treatment and toxicity.
case_images: fonc-14-1330271-g003.jpg
case_images: PMC10896602_01_fonc-14-1330271-g003.jpg
case_images: f3